Zobrazeno 1 - 10
of 16
pro vyhledávání: '"D D Baidildina"'
Autor:
G A Novichkova, M A Maschan, I P Shipitsyna, Yu V Skvortsova, M I Persiantseva, L L Lebedeva, V O Bobrynina, D D Baidildina, O V Goronkova, G G Solopova, L A Khachatryan, U N Petrova, E V Suntsova, I I Kalinina, V V Sinitsyna, E V Skorobogatova, D N Balashov, Z M Dyshlevaya, L N Shelikhova, E E Kurnikova, P E Trakhtman, A A Maschan
Publikováno v:
Терапевтический архив, Vol 82, Iss 7, Pp 41-47 (2010)
Aim. To analyze the efficiency of transplantation of the bone marrow from a HLA-compatible unrelated donor and continued immunosuppressive therapy (IST) in children with aplastic anemia (AA) unresponsive to 2 courses of IST. Subjects and methods. The
Externí odkaz:
https://doaj.org/article/a539b74b2830479ca8268ed25335826e
Autor:
Z M Dyshlevaya, E V Skorobogatova, M A Maschan, I P Shipitsyna, Yu V Skvortsova, P E Trakhtman, D N Balashov, Yu V Pashko, E E Kurnikova, E V Suntsova, O V Goronkova, G G Solopova, D D Baidildina, I I Kalinina, L A Khachatryan, M M Shneider, A A Maschan
Publikováno v:
Терапевтический архив, Vol 82, Iss 7, Pp 34-40 (2010)
Aim. To analyze the results of allogeneic and autologous hemopoietic cell transplantations (allo- and auto-HCT) in children with acute myeloid leukemia (AML) from an intermediate risk group, most of which were performed using lower-intensity conditio
Externí odkaz:
https://doaj.org/article/10dd86ccbaa341b7856c227fcea1b525
Autor:
D D Baidildina, M A Maschan, E V Skorobogatova, M E Dubrovina, Yu V Rumyantseva, A A Maschan, A G Rumyantsev, E V Samochatova
Publikováno v:
Терапевтический архив, Vol 82, Iss 7, Pp 20-25 (2010)
Aim. To analyze the specific features of recurrences of acute promyelocytic leukemia (APL) in children after standard therapy with daunorubicin, cytosine arabinoside (Ara-C), all-trans retinoic acid (ATRA) and to develop further programmed treatment
Externí odkaz:
https://doaj.org/article/5e62b3f9a57b4cd8bfe665f6abeecb61
Autor:
E. V. Samochatova, D. D. Baidildina, M. A. Maschan, N. N. Savva, O. P. Khlebnikova, A. V. Shamardina, Yu. E. Mareiko, G. A. Tsaur, T. O. Riger, M. M. Shneider, Yu. V. Rumyantseva, T. V. Nasedkina, T. V. Savitskaya, A. A. Maschan
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 8-17 (2022)
The use of all-trans retinoic acid (ATRA) drastically improved the results of therapy for acute promyelocytic leukeimia (APL). The high efficiency of the Russian protocol APL-93—98 applied to 62 children and adolescents with APL (event-free and ove
Externí odkaz:
https://doaj.org/article/a1999c503e6849b689ddc0507d049b22
Autor:
G. G. Solopova, D. D. Baidildina, L. I. Zharikova, I. I. Kalinina, U. N. Petrova, Ye. V. Suntsova, O. V. Goronkova, L. A. Hachatryan, V. V. Sinitsina, G. A. Novichkova, A. A. Maschan, M. A. Maschan
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 8-15 (2022)
Standard therapy of high risk patients with Langerhans cell histiocytosis (LCH) is associated with essential risk of therapy failure. In the present study results of 2-clorodeoxyadenosine usage as alternative therapy in this group of patients are ana
Externí odkaz:
https://doaj.org/article/aff35ebb6ec14d3cbe54f0f6a680cf5f
Autor:
N. P. Kirsanova, O. V. Aleinikova, A. M. Kustanovich, T. V. Savitskay, R. I. Yutskevich, E. V. Volochnik, L. V. Baidun, Yu. E. Mareiko, Yu. S. Strongin, N. V. Minakovskay, N. V. Migal, I. V. Proleskovskay, I. V. Emelyanova, O. V. Karas, A. G. Drekov, M. M. Maschan, D. V. Litvinov, N. V. Myakova, E. V. Skorobogatova, D. D. Baidildina, I. I. Kalinina, G. G. Solopova, E. V. Suntsova, U. N. Petrova, L. A. Hachatryan, M. M. Scheider, A. A. Maschan
Publikováno v:
Онкогематология, Vol 0, Iss 1, Pp 5-13 (2022)
Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with primary acute myeloid leukemia (AML) in Russia and Belarus are presented. 105 children at the age from 2 weeks till 18 years (a median age — 10.8 years) are inc
Externí odkaz:
https://doaj.org/article/b5947a60a3844a338c3bdb12bb102b9d
Autor:
L. A. Khachatrian, M. A. Maschan, Ye. V. Samochatova, M. M. Schneider, D. D. Baidildina, G. G. Solopova, Ye. V. Suntzova, L. I. Zjarikova, U. N. Petrova, V. V. Sinitsina, G. A. Novichkova, A. A. Maschan
Publikováno v:
Онкогематология, Vol 0, Iss 1-2, Pp 34-38 (2022)
Prognosis of patients with juvenile myelomonocytic leukemia not undergoing allogeneic hematopoietic cells transplantation (SCT) is dismal and not affected by any cytotoxic chemotherapy. Differentiating therapy is an attractive approach in JMML, due t
Externí odkaz:
https://doaj.org/article/fd2660cb6eaf48aa8f9d1014cd95ecab
Autor:
S. K. Arakelyan, S. L. Blagov, S. I. Kovrygin, A. A. Semchenkova, M. S. Fadeeva, D. A. Evseev, T. Yu. Salimova, D. D. Baidildina, L. N. Shelikhova, M. A. Maschan, A. A. Maschan
Publikováno v:
Pediatric Hematology/Oncology and Immunopathology. 22:104-112
Pure red cell aplasia (PRCA) is a rare complication of AB0-incompatible allogeneic hematopoietic stem cell transplantation, which manifests as a partial or complete absence of erythroid lineage in recipients with normal function of other hematopoieti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94e77c6c761e68bb38a43c5ce7f8091f
https://doi.org/10.24287/1726-1708-2023-22-2-104-112
https://doi.org/10.24287/1726-1708-2023-22-2-104-112
Autor:
E. I. Lyudovskikh, D. A. Evseev, D. S. Osipova, E. V. Raykina, I. I. Kalinina, D. D. Baidildina, A. A. Maschan, M. A. Maschan
Publikováno v:
Pediatric Hematology/Oncology and Immunopathology. 22:122-125
Here we report a clinical case of a patient with BRAF-positive Langerhans cell histiocytosis treated with combination therapy including trametinib. As the patient was undergoing long-term therapy with a BRAF inhibitor, his underlying disease reactiva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc1e84e29d5ce22dc9b4267f51c05542
https://doi.org/10.24287/1726-1708-2023-22-1-122-125
https://doi.org/10.24287/1726-1708-2023-22-1-122-125
Autor:
I. I. Kalinina, D. A. Venyov, Yu. V. Olshanskaya, M. N. Sadovskaya, O. V. Goronkova, T. Yu. Salimova, U. N. Petrova, D. D. Baidildina, E. V. Suntsova, D. A. Evseev, V. E. Matveev, K. S. Antonova, I. G. Khamin, M. Е. Dubrovina, E. A. Zerkalenkova, M. V. Gaskova, A. M. Popov, S. A. Kashpor, A. I. Mandzhieva, T. V. Konyukhova, L. A. Khachatryan, D. V. Litvinov, D. N. Balashov, L. N. Shelikhova, M. A. Maschan, G. A. Novichkova, A. A. Maschan
Publikováno v:
Pediatric Hematology/Oncology and Immunopathology. 21:20-35
Over the past years, the outcomes of patients with acute myeloid leukemia (AML) have significantly improved due to the use of intensive chemotherapy, more effective supportive therapy, and the availability of allogeneic hematopoietic stem cell transp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::552ffa7a0d0e84579992ae4d12a8081b
https://doi.org/10.24287/1726-1708-2022-21-1-20-35
https://doi.org/10.24287/1726-1708-2022-21-1-20-35